[Coagulation dysfunctions in patients with systemic inflammatory response syndrome]

Zhonghua Nei Ke Za Zhi. 2004 Feb;43(2):94-7.
[Article in Chinese]

Abstract

Objective: To study the effects of coagulation dysfunctions on patients with the development of systemic inflammatory response syndrome (SIRS).

Methods: All the patients studied were divided into 2 groups: SIRS and non-SIRS according to the criteria for selection of SIRS. The SIRS group included 100 patients and the non-SIRS group 50 patients. A control group included 50 healthy adults. SIRS group was further divided into two subgroups: survivor and non-survivor. Levels of platelet (PLT), D-dimer, protein C (PC), protein S (PS), antithrombin III (ATIII), thrombomodulin (TM), tissue plasminogen activator (TPA), plasminogen-activator inhibitor (PAI-1), prothrombin test (PT), thrombin time (TT), activated partial thromboplastin time (APTT) and fibrinogen (FBG) were measured in all the patients and healthy persons.

Results: (1) Levels of TT, APTT, PT, D-dimer, TM, PAI-1 were significantly higher in SIRS than those in non-SIRS and the control group (P < 0.05). Levels of PC, PS, TPA, PLT, FBG were significantly lower in SIRS group than those in non-SIRS and the control group (P < 0.05). (2) Levels of ATIII were not different among SIRS, non-SIRS and the control group (P > 0.05). (3) Survivors levels of D-dimer, APTT and PAI-1 in SIRS group were significantly higher than there in non-survivors (P < 0.05); they were both negatively correlated with the prognosis of SIRS (P < 0.01).

Conclusions: (1) There are dysfunctions of coagulation in patients with systemic inflammatory response syndrome. (2) Fibrinolytic system plays an important role in the development of SIRS. (3) Levels of PAI-1 and D-dimer are both negatively correlated with the prognosis of SIRS.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Blood Coagulation Disorders / etiology*
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Fibrinolysis
  • Humans
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / blood
  • Systemic Inflammatory Response Syndrome / blood*

Substances

  • Fibrin Fibrinogen Degradation Products
  • Plasminogen Activator Inhibitor 1
  • fibrin fragment D